Cytogenetic characteristics of and prognosis for acute myeloid leukemia in 107 children

Chen, Wanzi; Yang, Jinghui; Chen, Ping

doi:10.2478/abm-2021-0010

Abstract

Background

Patients diagnosed with acute myeloid leukemia (AML) in childhood have a poor prognosis. A better understanding of prognostic factors will assist patients and clinicians in making difficult treatment decisions.

Objectives

To understand further the cytogenetic characteristics of and reassess the prognostic value of cytogenetic abnormalities in childhood AML.

Methods

Conventional karyotypes of 107 children with AML were analyzed retrospectively. The cases were divided into 4 groups based on genetic rearrangements; namely patients with: t(15;17)/PML-RARA; t(8;21)/RUNX1-RUNX1T1 or inv(16)(p13;q22) and t(16;16)/CBFB-MYH11; −7 or complex karyotypes; normal karyotypes or other cytogenetic changes. Differences in age, sex, leukocyte count, event-free survival (EFS), and overall survival (OS) were analyzed.

Results

All French-American-British (FAB) subtypes of AML were detected in 107 patients. We successfully cultured 81 of 107 bone marrow specimens, of which 60 cases had abnormal karyotypes. The most common abnormal karyotypes were t(8;21) (17/81 cases), followed by t(15;17) (13/81 cases), –X/Y (10/81 cases). There were no significant differences (P > 0.05) in age, sex, or leukocyte counts between the 4 groups. The differences in 3-year EFS and OS between each pair were significant, except for groups of patients with t(8;21)/RUNX1-RUNX1T1 and patients with normal karyotypes or other cytogenetic changes (P = 0.054).

Conclusions

Chromosomal abnormalities may provide important prognostic factors for AML in children and be helpful for risk stratification and individual treatment.

References

Zhai XW, Cheng FWT, Lee V, Leung WK, Ng MHL, Tsang KS, et al. Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children. Pediatr Hematol Oncol. 2011; 28:269–78.
Search in Google Scholar Back to article
Vedi A, Mitchell R, Shanmuganathan S, Oswald C, Marshall GM, Trahair T, et al. Increased survival for children with acute myeloid leukemia results from improved postrelapse treatment. J Pediatr Hematol Oncol. 2018; 40:541–7.
Search in Google Scholar Back to article
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012; 120:3187–205.
Search in Google Scholar Back to article
Kairiene I, Pasauliene R, Lipunova N, Vaitkeviciene G, Rageliene L, Rascon J. Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience. Eur J Pediatr. 2017; 176:1329–37.
Search in Google Scholar Back to article
Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012; 119:5980–8.
Search in Google Scholar Back to article
Klein K, de Haas V, Kaspers GJL. Clinical challenges in de novo pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2018; 18:277–93.
Search in Google Scholar Back to article
Lins MM, Mello MJG, Ribeiro RC, De Camargo B, de Fátima Pessoa Militão, de Albuquerque M, Thuler LCS. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low–middle-income country. Ann Hematol. 2019; 98:1403–11.
Search in Google Scholar Back to article
Xing S, Wang B, Gao Y, Li M, Wang T, Sun Y, et al. Cytogenetics and associated mutation profile in patients with acute monocytic leukemia. Int J Lab Hematol. 2019; 41:485–92.
Search in Google Scholar Back to article
Iijima-Yamashita Y, Matsuo H, Yamada M, Deguchi T, Kiyokawa N, Shimada A, et al. Multiplex fusion gene testing in pediatric acute myeloid leukemia. Pediatr Int. 2018; 60:47–51.
Search in Google Scholar Back to article
Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, et al. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. 2017; 129:3051–8.
Search in Google Scholar Back to article
McNeer NA, Philip J, Geiger H, Ries RE, Lavallée VP, Walsh M, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019; 33:1934–43.
Search in Google Scholar Back to article
Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013; 122:170–8.
Search in Google Scholar Back to article
Subspecialty Group of Hematology Diseases; Society of Pediatrics; Chinese Medical Association; Editorial Board of Chinese Journal of Pediatrics, Lungjun G, et al. [Recommendations for diagnosis and treatment of acute myelocytic leukemia in children]. Zhonghua Er Ke Za Zhi. [Chin J Pediatr]. 2006; 44:877–8. [in Chinese]
Search in Google Scholar Back to article
Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Br J Cancer. 2015; 112:251–9.
Search in Google Scholar Back to article
O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, et al. Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15:926–57.
Search in Google Scholar Back to article
Jastaniah W, Bayoumy M, Alsultan A, Al Daama S, Ballourah W, Al-Anzi F, et al. Identifying prognostic factors that influence outcome of childhood acute myeloid leukemia in first relapse in Saudi Arabia: results of the multicenter SAPHOS Study. Clin Lymphoma Myeloma Leuk. 2018; 18:773–80.
Search in Google Scholar Back to article
Ruan M, Wang Y-Q, Zhang L, Zou Y, Zhu X-F. [Analyses of karyotypic characteristics and prognosis in pediatric acute myeloblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. [Chin J Hematol]. 2012; 33:725–8. [in Chinese, English abstract].
Search in Google Scholar Back to article
Sandahl JD, Kjeldsen E, Abrahamsson J, Ha SY, Heldrup J, Jahnukainen K, et al. Ploidy and clinical characteristics of childhood acute myeloid leukemia: A NOPHO-AML study. Genes Chromosomes Cancer. 2014; 53:667–75.
Search in Google Scholar Back to article
So C-C, Wan TS, Chow JL, Hui K-C, Choi WW, Lam CC, Chan L-C. A single-center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia—evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients. Cancer Genet. 2011; 204:430–8.
Search in Google Scholar Back to article
Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014; 28:1449–58.
Search in Google Scholar Back to article
Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DKH, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010; 28:2674–81.
Search in Google Scholar Back to article
Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005; 106:447–453.
Search in Google Scholar Back to article
Betts DR, Ammann RA, Hirt A, Hengartner H, Beck-Popovic M, Kuhne T, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol. 2007; 78:468–76.
Search in Google Scholar Back to article
Kömür M, Erbey F, Bayram I, Tanyeli A. Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia. Asian Pac J Cancer Prev. 2010; 11:1393–5.
Search in Google Scholar Back to article
Moarii M, Papaemmanuil E. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematology Am Soc Hematol Educ Program. 2017; 2017:37–44.
Search in Google Scholar Back to article
Gong XY, Wang Y, Liu BC, Wei H, Li CW, Li QH, et al. [Characteristics and prognosis in adult acute myeloid leukemia patients with MLL gene rearrangements]. Zhonghua Xue Ye Xue Za Zhi [Chin J Hematol]. 2018; 39:9–14. [in Chinese, English abstract]
Search in Google Scholar Back to article
He J, Xue Y, He H, Li J, Song X, Huang Y, et al. [Clinical and biological characteristics in childhood acute myeloid leukemia with 8;21 translocation]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi [Chin J Med Genetics]. 2004; 21:512–4. [in Chinese, English abstract].
Search in Google Scholar Back to article
Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2018; 59:2273–86.
Search in Google Scholar Back to article
Wang CL, Ding BJ, Jiang L, Yin CX, Zhong QX, Yu GP, et al. Increased expression of amyloid precursor protein promotes proliferation and migration of AML1/ETO-positive leukemia cells and be inhibited by panobinostat. Neoplasma. 2015; 62:864–71.
Search in Google Scholar Back to article
Kim M, Kim J, Kim JR, Han E, Park J, Lim J, et al. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1. Mol Biol Rep. 2015; 42:451–6.
Search in Google Scholar Back to article
Ding C, Chen S-N, Macleod RAF, Drexler HG, Nagel S, Wu D-P, et al. MiR-130a is aberrantly overexpressed in adult acute myeloid leukemia with t(8;21) and its suppression induces AML cell death. Ups J Med Sci. 2018; 123:19–27.
Search in Google Scholar Back to article
Debaize L, Jakobczyk H, Avner S, Gaudichon J, Rio A-G, Sérandour AA, et al. Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation. Nucleic Acids Res. 2018; 46:11214–228.
Search in Google Scholar Back to article
Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, et al. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Ann Hematol. 2019; 98:83–91.
Search in Google Scholar Back to article